2022 World Conference on Lung Cancer (ePosters)-EP08.01-078. Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors

EP08.01-078. Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors

Back to course

Pdf Summary

This study examined the clinical outcomes of patients with metastatic non-small cell lung cancer (NSCLC) harboring BRAF mutations who were treated with immune checkpoint inhibitors (ICI). The researchers retrospectively reviewed the records of 33 patients with BRAF-mutated metastatic NSCLC and analyzed their clinical outcomes using RECIST 1.1 criteria.<br /><br />The primary endpoints of the study were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included objective response rate (ORR) and subgroup analysis according to the type of BRAF mutation (V600E vs. other pathogenic mutations), programmed cell-ligand 1 (PD-L1) status, and line of ICI therapy.<br /><br />The results showed that the median OS of the entire cohort was 13.2 months. Patients with BRAF V600E mutation had a median OS of 6.6 months, while those with BRAF non-V600E mutation had a median OS of 29.9 months. Among patients who received ICI, the median PFS was 11.6 months. PFS was longer in PD-L1 positive patients compared to PD-L1 negative patients, and earlier initiation of ICI therapy was associated with better PFS.<br /><br />The overall response rate to ICI treatment was 31.25%, and the disease control rate was 68.75%. The study also found that patients treated with ICI in the first-line setting had a longer median PFS compared to those treated in the second-line or beyond.<br /><br />In conclusion, this study suggests that immune checkpoint inhibitors may have efficacy in treating BRAF-mutated NSCLC. The results also indicate that PD-L1 positivity and earlier initiation of ICI therapy are associated with improved clinical outcomes. However, the sample size of patients with BRAF V600E mutation was too small to draw definitive conclusions about this subgroup. Further research with larger cohorts is needed to validate these findings.

Asset Subtitle

Susana Cedres

Meta Tag

Speaker Susana Cedres

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

metastatic non-small cell lung cancer

BRAF mutations

immune checkpoint inhibitors

clinical outcomes

RECIST 1.1 criteria

progression-free survival

overall survival

objective response rate

PD-L1 status

first-line setting